Do You Need to Taper Off Wegovy Before Stopping?

What clinical trials tell us happens when semaglutide stops

The clearest evidence comes from the STEP 1 extension study, which followed participants for a year after they stopped semaglutide 2.4 mg. On average, participants regained around two-thirds of the weight they had lost within twelve months of stopping, and if you are wondering about what a Wegovy taper off schedule actually involves, the data make sobering reading: no taper schedule made a material difference to that trajectory. The original STEP 1 trial, published in the New England Journal of Medicine, had shown around 15% average weight reduction at 68 weeks. The rebound data make clear that the medicine is doing continuous work while you take it; stopping removes that effect, and a stepped reduction does not meaningfully slow the rebound.

There is no published evidence that tapering semaglutide preserves weight loss better than an abrupt stop. That is partly why no formal taper protocol appears in the licensed prescribing information. The medicine's long half-life (roughly one week) means concentrations fall gradually on their own after the last injection, which is itself a kind of natural step-down. Your body gets a slower exit than you might expect from a weekly drug.

None of this means stopping is trivial. It means the right question is not "which taper schedule" but "should I be stopping at all, and what happens next."

Why a prescriber might still suggest stepping doses down

The absence of a pharmacological tapering requirement does not mean every clinician takes an abrupt approach. Some prescribers choose a step-down for practical reasons: moving from 2.4 mg to 1.7 mg to 1.0 mg over a few months can help patients who are nervous about how their appetite will respond, giving them time to reinforce the eating habits built during treatment. It can also ease the transition for people who experienced significant nausea at the higher dose and want to avoid re-experiencing that in reverse.

There is also a subset of patients for whom stopping is not a free choice, supply interruptions, cost changes, or a planned surgical procedure may require a pause. Whether you have to taper off Wegovy in those circumstances is a different question from whether it helps, and the answer often depends on how long the break is expected to last.

The NHS England guidance on weight-management injections emphasises that stopping decisions should happen within a supported clinical relationship, not unilaterally, which is good advice whether your plan involves a taper or not.

A practical note: if you are managing your treatment around life events, remember that same-day prescriber reviews at a registered online pharmacy mean you are not locked into waiting days for clinical input when your situation changes.

What actually happens to weight after stopping, and what helps

The rebound effect after stopping semaglutide is well documented and reflects the underlying biology rather than a failure of effort. Wegovy works partly by reducing appetite signals and slowing gastric emptying; when those effects lift, hunger tends to return. For many people it returns noticeably, sometimes more acutely in the weeks immediately after stopping than it was before they started. That is not universal, and some people find the behavioural habits they built during treatment carry significant weight on their own. But planning for the possibility of increased appetite is realistic, not pessimistic.

If you are thinking about stopping because of cost, it is worth reading about how Wegovy is priced in the UK private market before making that decision, there may be options worth discussing with your prescriber first. Treatment does not have to be all-or-nothing.

For those who do stop, the evidence points to lifestyle as the main buffer. Protein adequacy, resistance exercise, and regular meals help stabilise appetite in the months after discontinuation. Your prescriber or a dietitian is best placed to build that plan around your individual circumstances. Stopping abruptly on a Friday afternoon because the pen ran out is a different experience from stopping with a plan in place, the former is common, the latter is better.

When to talk to your prescriber before making any change

There are situations where stopping Wegovy without clinical input carries a specific risk. If you are taking semaglutide for cardiovascular risk reduction alongside weight management, the calculus of stopping is different from stopping for weight management alone. If you have type 2 diabetes managed partly through the metabolic effects of semaglutide, a blood glucose review before stopping is sensible. Pregnancy planning is another context: current guidance recommends stopping semaglutide and allowing a wash-out period before trying to conceive, and that timing should be agreed with a prescriber rather than estimated.

Anyone curious about whether weaning off Wegovy is necessary in their specific situation will get a more useful answer from a prescriber who has seen their consultation history than from a general article, this one included. The general answer is no, tapering is not a clinical requirement. The personal answer may be more nuanced.

Our clinical team at nume reviews every repeat and every stopping decision individually, and if you have ever found yourself unsure about how often you need to take Wegovy or what missing a dose means for your plan, that is exactly the kind of question worth raising in a consultation. If you are weighing up whether to continue, pause, or stop your treatment, a free consultation is the right starting point.